EGFR and neoplasm: For instance, in 50%–60% of cases, treating an EGFR-mutant primary tumor with targeted therapies induces a positive selection of resistant cancer cells within the tumor due to the acquisition of a secondary mutation, T790M in the EGFR protein that occurs outside of the ATP binding site [41].